Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced ovarian cancer (for recurrent disease only) (Review of TA 91 & TA 222)
| Status: |
In development
|
| Expected date of issue: |
TBC |
| Process: |
MTA |
Topic area:
-
Cancer
-
Gynaecology, pregnancy and birth
|
NICE project team
| Executive Lead: |
TBC
|
| Technical Lead: |
Helen Tucker
|
| Communications manager: |
Laura Gibson
|
| Project manager: |
Bijal Joshi
|
Provisional schedule
| Closing date for invited submissions / evidence submission: |
13 March 2013 |
| 1st appraisal committee meeting: |
04 September 2013 |
| 2nd appraisal committee meeting: |
06 November 2013 |
Consultees and commentators
Project history
| Date |
Update |
| 07 January 2015 |
Please note that the appeal period for this appraisal will close at 5pm 20 January 2015 |
| 09 December 2013 |
The release of the FAD has been delayed.
We will provide you with an update as soon as we have further information.
|
| 12 February 2013 |
Trabectedin in combination with pegylated liposomal doxorubicin hydrochloride was omitted from the list of relevant interventions for people who are allergic to platinum-based compounds. This omission has been corrected in final scope.
|
|
Key documents
 |
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): appeal
|
03 February 2015 |
|
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468]: final appraisal determination
|
06 January 2015 |
|
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): appraisal consultation
|
27 September 2013 |
 |
Ovarian Cancer Topotecan Pegylated Liposomal Doxorubicin Hydrochloride Paclitaxel Trabectedin and Gemcitabine (Review) Assessment Report - Consultation
|
22 July 2013 |
|
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): final protocol
|
18 December 2012 |
|
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): final scope (post CIM)
|
12 February 2013 |
|
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): final matrix
|
28 November 2012 |
|
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): NICE response to consultee and commentator comments on the draft scope
|
28 November 2012 |
|
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): equality impact assessment form - scoping
|
28 November 2012 |
|
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only: draft scope
|
05 September 2012 |
|
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only: draft matrix
|
05 September 2012 |
|
This page was last updated: 24 April 2015